DURECT (NASDAQ:DRRX) Coverage Initiated by Analysts at StockNews.com

Analysts at StockNews.com assumed coverage on shares of DURECT (NASDAQ:DRRXGet Free Report) in a report released on Wednesday. The brokerage set a “sell” rating on the specialty pharmaceutical company’s stock.

Separately, HC Wainwright reissued a “neutral” rating on shares of DURECT in a report on Thursday, November 14th.

Get Our Latest Research Report on DURECT

DURECT Trading Down 1.0 %

Shares of DRRX opened at $0.84 on Wednesday. DURECT has a 12 month low of $0.68 and a 12 month high of $1.88. The stock’s 50 day moving average is $0.88 and its two-hundred day moving average is $1.22. The firm has a market cap of $26.13 million, a P/E ratio of -1.38 and a beta of 0.94.

Hedge Funds Weigh In On DURECT

A hedge fund recently raised its stake in DURECT stock. Geode Capital Management LLC grew its holdings in DURECT Co. (NASDAQ:DRRXFree Report) by 4.8% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 319,905 shares of the specialty pharmaceutical company’s stock after purchasing an additional 14,658 shares during the quarter. Geode Capital Management LLC owned about 1.03% of DURECT worth $429,000 as of its most recent SEC filing. 28.03% of the stock is owned by hedge funds and other institutional investors.

About DURECT

(Get Free Report)

DURECT Corporation, a biopharmaceutical company, develops medicines based on its epigenetic regulator program. The company's lead product larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis.

Featured Articles

Receive News & Ratings for DURECT Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DURECT and related companies with MarketBeat.com's FREE daily email newsletter.